Thursday, July 3, 2025 7/3/2025

Improving diagnostic US for reduction of benign breast biopsies using US-guided Optical Tomography

Award Number: R01CA228047
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/13/2018
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Improving diagnostic US for reduction of benign breast biopsies using US-guided Optical Tomography - Title: Improving diagnostic US specificity on breast biopsies using US-guided Diffuse Optical Tomography Abstract In current clinical practice, while the characteristics of malignant and benign breast lesions are well established by conventional imaging techniques, the overlapping appearances of malignant and benign lesions have prompted radiologists to recommend biopsy for most low and moderate risk breast lesions. As a result, in the United States, approximately one million image-guided breast biopsies are performed each year, with the majority of the lesions yielding benign results. Many attempts to improve this situation have not been successful. This application will explore the potential impact of Ultrasound (US)-guided diffuse optical tomography (DOT) as an adjunct to US in a diagnostic setting, with the goal of reducing benign biopsies without compromising cancer detection sensitivity. US-guided DOT provides hemoglobin concentration values and distributions which in turn map out lesion vascularity or angiogenesis. Recently, we retrospectively evaluated 288 patients to assess the potential clinical impact of our technique in characterizing low and moderate risk breast lesions, which might not need to be biopsied if the US-guided DOT technology were used in the biopsy decision making process. In this patient cohort, the total hemoglobin level combined with two radiologists’ diagnosis achieved high sensitivity of 96.6-100% on cancer detection and negative predictive value of 99-100%. Using a conservative threshold for the total hemoglobin (tHb) data to differentiate lesions based on the amount of vascularity, we found the number of lesions that would be referred to biopsy decreased by approximately 45% on average, while maintaining high detection sensitivity. Our hypotheses are: 1) The first hypothesis is that the measured tHb values and distribution can be potentially used as an adjunct for radiologists to reduce unnecessary biopsies in low risk patients with benign pathological results; and 2) The second hypothesis is that while reducing unnecessary benign biopsies, the addition of adjunct information from US-guided DOT still maintains a high sensitivity of capturing nearly all malignant tumors. In this application, we propose three aims: 1) Optimization and validation of a new non-iterative imaging reconstruction algorithm and new statistical methods for automated data processing, robust data selection, with the goal of near real-time imaging for onsite diagnosis by physicians. This is a significant step forward to bring this technology into clinics; 2) To prospectively assess the impact of adjunctive US-guided DOT to conventional breast imaging on accurate breast cancer diagnosis and reduction of benign biopsy. Approximate 300 patients will be recruited at the Radiology Department of Washington University to validate the early retrospective results; and 3) Perform statistical analysis to validate the reduction of benign biopsy while maintaining high sensitivity. The successful completion of the project will help initiate a paradigm shift in how we manage low risk benign lesions without compromising cancer detection sensitivity in current clinical practice and will reduce health care cost without compromising patient care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	5	11/6/2024	NON-COMPETING CONTINUATION	$0
2025	2023	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	001	5	2/13/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $386,028 )
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	001	5	3/15/2023	NON-COMPETING CONTINUATION	$31,511
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	5	12/1/2022	NON-COMPETING CONTINUATION	$354,517
														Subtotal = $386,028

Issue Date FY: 2022 ( Subtotal = $386,028 )
2022	2022	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	4	12/15/2021	NON-COMPETING CONTINUATION	$354,516
2022	2022	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	001	4	5/20/2022	NON-COMPETING CONTINUATION	$31,512
														Subtotal = $386,028

Issue Date FY: 2021 ( Subtotal = $393,908 )
2021	2021	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	3	11/18/2020	NON-COMPETING CONTINUATION	$374,212
2021	2021	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	001	3	1/22/2021	NON-COMPETING CONTINUATION	$19,696
														Subtotal = $393,908

Issue Date FY: 2020 ( Subtotal = $393,178 )
2020	2020	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	2	11/21/2019	NON-COMPETING CONTINUATION	$353,859
2020	2020	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	001	2	1/14/2020	NON-COMPETING CONTINUATION	$39,319
														Subtotal = $393,178

Issue Date FY: 2019 ( Subtotal = $390,469 )
2019	2019	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Detection and Diagnosis Research	000	1	12/13/2018	NEW	$390,469
														Subtotal = $390,469

Grand Total All Awards = $1,949,611

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving diagnostic US for reduction of benign breast biopsies using US-guided Optical Tomography

Award Number: R01CA228047

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/13/2018

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer